Recruiting
Phase 1

Lobeline

Sponsor:

National Institute on Drug Abuse (NIDA)

Code:

NCT00439504

Conditions

Methamphetamine Dependence

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Interventions

Lobeline

Study Details

Brief summary:

The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.

Conditions

Methamphetamine Dependence

Study ID

NCT00439504

Status verified date

Feb, 2007

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Be between the ages of 18 and 45 years of age
  • Be in general good health with a history of methamphetamine (MA) abuse (but not dependence)
  • If female and of child bearing potential, agrees to use birth control
  • Be able to understand and provide written informed consent
  • Have a body mass index between 18 and 30
  • Have reported use of (MA) during the past three months without experiencing adverse consequence plus a life time MA or amphetamine use history of at least four occasions of use
  • Have a negative drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening and at the time of admission

Exclusion Criteria:

  • Please contact site for details

Study Design

Enrollment

10 participants

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

Lobeline

Primary outcome measure

  • Cardiovascular responses [ Time Frame: undefined ]

Central Contacts and Locations

Locations

Langley Porter Psychiatric Institute

Recruiting

San Francisco, California, United States, 94143

Contacts

Reese Jones, M.D.

415-476-7452reese@itsa.ucsf.edu

More Information

Sponsor

National Institute on Drug Abuse (NIDA)

Last update posted

Jan 11, 2017

Last verified

Feb, 2007

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA) on 2017-01-11.